Long QT syndrome 3
MONDO:0011377An autosomal dominant condition caused by mutation(s) in the SCN5A gene, encoding sodium channel protein type 5 subunit alpha. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.
Also known as: LQT3, SCN5A long QT syndrome, long QT syndrome 3, long QT syndrome caused by mutation in SCN5A, long QT syndrome type 3, long QT syndrome 2/3, digenic, long QT syndrome 3, acquired, susceptibility to, long QT syndrome 3/6, digenic
35 clinical trials for this condition and its sub-types, 6 tagged with Long QT syndrome 3 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug aims to tame dangerous heart rhythms in genetic disorder
Disease control Recruiting nowThis study tests whether the drug THRV-1268 can safely shorten the heart's electrical recovery time (QT interval) in people with Long QT Syndrome Type 2, a genetic condition that raises the risk of dangerous heart rhythms and sudden cardiac arrest. About 64 participants will take…
Phase 2/3 • Sponsor: Thryv Therapeutics, Inc. • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
Immune clues in the blood may predict IVF success
Knowledge-focused Recruiting nowThis study tracks immune-related substances in the blood of 40 women undergoing a frozen embryo transfer. Researchers want to see how these markers change before and after the transfer, and whether they relate to pregnancy success. The goal is to better understand the role of the…
Sponsor: ART Fertility Clinics LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Heart condition's hidden toll: new study asks patients about life quality
Knowledge-focused Recruiting nowThis study aims to understand how Long QT Syndrome types 2 and 3 affect the quality of life and daily burden of adults. Researchers will ask up to 200 participants to fill out questionnaires about their physical, emotional, and social well-being. No treatment is given; the goal i…
Sponsor: Thryv Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC